PMID- 16574034
OWN - NLM
STAT- MEDLINE
DCOM- 20060810
LR  - 20151119
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 22
IP  - 3
DP  - 2006 Mar
TI  - A comparison of the skin irritation potential of transdermal fentanyl versus 
      transdermal buprenorphine in middle-aged to elderly healthy volunteers.
PG  - 501-9
AB  - OBJECTIVE: Establishing local tolerability of transdermal opioid systems is 
      important as more systems become available for use in a range of indications. We 
      compared the skin irritation potential of a single application of transdermal 
      fentanyl (Durogesic D-trans; DDTDF) and transdermal buprenorphine (Transtec; TDB) 
      patches in healthy volunteers. METHODS: 46 healthy males and females (mean age 
      [range]: 59.6 [50-69] years) with healthy skin received a single dose of both the 
      DDTDF 25 mug/h patch and the TDB 35 mug/h patch in a randomised order under 
      naltrexone cover. The incidence and severity of erythema was assessed at various 
      timepoints after patch removal. RESULTS: There was a non-significant trend 
      towards a higher incidence of erythema 60 min after patch removal with TDB 
      compared with DDTDF. The severity of erythema at 60 min and the incidence of 
      erythema at 72 h after patch removal were significantly higher with TDB than with 
      DDTDF (p = 0.01 and 22% versus 4.9%, p = 0.04, respectively). In general, the 
      results from the chromametric assessment of treated skin were in agreement. The 
      incidence of topical adverse events (AEs) was lower with DDTDF than with TDB (one 
      versus six events) and subjects preferred the DDTDF patch and felt it was less 
      noticeable on the skin. The DDTDF patch was considered less painful to remove, 
      and, consistent with that, the TDB patch was judged to have better adhesion. 
      Twenty-one subjects reported systemic AEs with DDTDF plus naltrexone and 22 with 
      TDB plus naltrexone, most of which were considered treatment-related, 34 and 60 
      AEs, respectively. CONCLUSIONS: Local tolerability of transdermal opioid systems 
      should be considered when making a therapeutic choice. Even after a single 
      application in healthy volunteers, differences in local tolerability, assessed 
      both clinically and by chromametry, and patch comfort were shown between DDTDF 
      and TDB, in favour of DDTDF.
FAU - Schmid-Grendelmeier, Peter
AU  - Schmid-Grendelmeier P
AD  - University Hospital of Zurich, Zurich, Switzerland.
FAU - Pokorny, Rolf
AU  - Pokorny R
FAU - Gasser, Urs E
AU  - Gasser UE
FAU - Richarz, Ute
AU  - Richarz U
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Analgesics, Opioid)
RN  - 40D3SCR4GZ (Buprenorphine)
RN  - UF599785JZ (Fentanyl)
SB  - IM
MH  - Administration, Cutaneous
MH  - Aged
MH  - Analgesics, Opioid/administration & dosage/*adverse effects
MH  - Buprenorphine/administration & dosage/*adverse effects
MH  - Drug Delivery Systems
MH  - Erythema/*chemically induced
MH  - Female
MH  - Fentanyl/administration & dosage/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Skin/*drug effects
MH  - Statistics, Nonparametric
MH  - Surveys and Questionnaires
EDAT- 2006/04/01 09:00
MHDA- 2006/08/11 09:00
CRDT- 2006/04/01 09:00
PHST- 2006/04/01 09:00 [pubmed]
PHST- 2006/08/11 09:00 [medline]
PHST- 2006/04/01 09:00 [entrez]
AID - 10.1185/030079906X89829 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2006 Mar;22(3):501-9. doi: 10.1185/030079906X89829.